First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non–Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance-Reference-Cited by-同舟云学术

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non–Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance

Published:2018-07 Issue:7 Volume:13 Page:968-977
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ma Yuxiang,Zheng Xin,Zhao Hongyun,Fang Wenfeng,Zhang Yang,Ge Jieying,Wang Lu,Wang Weicong,Jiang Ji,Chuai Shaokun,Zhang Zhou,Xu Wanhong,Xu Xiao,Hu Pei,Zhang Li

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers;Shigematsu;J Natl Cancer Inst,2005

4. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

5. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases;International Journal of Molecular Sciences;2024-06-26

2. Development and validation of a deep learning-based model to predict response and survival of T790M mutant non-small cell lung cancer patients in early clinical phase trials using electronic medical record and pharmacokinetic data;Translational Lung Cancer Research;2024-04

3. Sijunzi Tang improves gefitinib resistance by regulating glutamine metabolism;Biomedicine & Pharmacotherapy;2023-11

4. Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators;Cancers;2023-10-16

5. The Application of Pyrrolo[2, 3-d]pyrimidine Scaffold in Medicinal Chemistry from 2017 to 2021;Mini-Reviews in Medicinal Chemistry;2023-06